Enveric Biosciences Inc., a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders, has announced the filing of a new provisional patent application. This application pertains to a newly identified group of molecules with potential to address neurodegenerative diseases. According to Enveric, these molecules might offer therapeutic candidates for conditions such as Alzheimer's Disease by promoting BDNF signaling, a known therapeutic target in neurodegenerative diseases. A prototype molecule from this family has demonstrated promising pharmacokinetic characteristics in preliminary in vivo testing. Further investigation is planned to explore the therapeutic potential of these molecules.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。